Comparison of the Efficacy and Safety of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stents in Patients With ST-Elevation Myocardial Infarction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Cheol Whan | - |
dc.contributor.author | Park, Duk-Woo | - |
dc.contributor.author | Lee, Seung-Hwan | - |
dc.contributor.author | Kim, Young-Hak | - |
dc.contributor.author | Hong, Myeong-Ki | - |
dc.contributor.author | Kim, Jae-Joong | - |
dc.contributor.author | Park, Seong-Wook | - |
dc.contributor.author | Yun, Sung-Cheol | - |
dc.contributor.author | Seong, In-Whan | - |
dc.contributor.author | Lee, Jae-Hwan | - |
dc.contributor.author | Lee, Nae-Hee | - |
dc.contributor.author | Cho, Yoon Haeng | - |
dc.contributor.author | Cheong, Sang-Sig | - |
dc.contributor.author | Lim, Do-Sun | - |
dc.contributor.author | Yang, Joo-Young | - |
dc.contributor.author | Lee, Sang-Gon | - |
dc.contributor.author | Kim, Kee-Sik | - |
dc.contributor.author | Yoon, Junohan | - |
dc.contributor.author | Jeong, Myung-Ho | - |
dc.contributor.author | Seung, Ki Bae | - |
dc.contributor.author | Hong, Taeg Jong | - |
dc.contributor.author | Park, Seung-Jung | - |
dc.date.accessioned | 2021-09-08T11:32:11Z | - |
dc.date.available | 2021-09-08T11:32:11Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2009-11-15 | - |
dc.identifier.issn | 0002-9149 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/118919 | - |
dc.description.abstract | Drug-eluting stents (DESs) are increasingly used for treatment of acute ST-segment elevation myocardial infarction (STEMI), but there are few comparisons of outcomes of various types of DES. We compared the efficacy and safety of zotarolimus-eluting stents (ZESs), sirolimus-eluting stents (SESs), and paclitaxel-eluting stents (PESs) in primary intervention for STEMI. This multicenter, prospectively randomized ZEST-AMI trial included 328 patients at 12 medical centers who were randomly assigned to ZES (n = 108), SES (n = 110), or PES (n = 110) deployment. The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months. Secondary end points included the individual components of the primary end point, late loss, angiographic restenosis, and stent thrombosis. Baseline clinical and angiographic characteristics were well matched. In-segment late loss (0.28 +/- 0.42 vs 0.46 +/- 0.48 vs 0.47 +/- 0.50 mm, respectively, p = 0.029) and restenosis rate (2.7% vs 15.9% vs 12.3%, respectively, p = 0.027) at 8 months were lowest in the SES group compared to the ZES and PES groups. At 12 months, cumulative incidence rates of primary end points in the ZES, SES, and PES groups were 11.3%, 8.2%, and 8.2%, respectively (p = 0.834). There were 2 acute (in the SES group) and 5 subacute (2 in the SES group and 3 in the PES group) stent thromboses. Incidence of death, recurrent MI, or ischemia-driven target vessel revascularization did not differ among the 3 groups. In conclusion, despite the difference in restenosis rate, the efficacy and safety of the 3 different DESs showed similar, acceptable results in the treatment of STEMI. (c) 2009 Elsevier Inc. All rights reserved. (Am J Cardiol 2009;104:1370-1376) | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC | - |
dc.subject | BARE-METAL STENTS | - |
dc.subject | UNCOATED STENTS | - |
dc.subject | OFF-LABEL | - |
dc.subject | IMPLANTATION | - |
dc.subject | METAANALYSIS | - |
dc.subject | ANGIOPLASTY | - |
dc.subject | ABCIXIMAB | - |
dc.subject | TIROFIBAN | - |
dc.subject | TRIALS | - |
dc.title | Comparison of the Efficacy and Safety of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stents in Patients With ST-Elevation Myocardial Infarction | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lim, Do-Sun | - |
dc.identifier.doi | 10.1016/j.amjcard.2009.06.059 | - |
dc.identifier.scopusid | 2-s2.0-72049099355 | - |
dc.identifier.wosid | 000271998500009 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CARDIOLOGY, v.104, no.10, pp.1370 - 1376 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.citation.title | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 104 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1370 | - |
dc.citation.endPage | 1376 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | BARE-METAL STENTS | - |
dc.subject.keywordPlus | UNCOATED STENTS | - |
dc.subject.keywordPlus | OFF-LABEL | - |
dc.subject.keywordPlus | IMPLANTATION | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | ANGIOPLASTY | - |
dc.subject.keywordPlus | ABCIXIMAB | - |
dc.subject.keywordPlus | TIROFIBAN | - |
dc.subject.keywordPlus | TRIALS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.